Cryopreserved Arterial Allografts and ABO and Rhesus Compatibility

Ann Vasc Surg. 2016 May:33:173-80. doi: 10.1016/j.avsg.2015.11.014. Epub 2016 Feb 22.

Abstract

Background: Arterial cryopreserved allografts are conduit of choice for arterial bypass in case of infection. They are sometimes submitted to accelerated degeneration: stenosis, thrombosis, or aneurysmal evolution. We hypothesized that ABO group and Rhesus compatibility could play a role in arterial cryopreserved allograft complications.

Methods: Patients who benefit from allograft bypass from 2006 to 2011 were retrospectively compared, regarding ABO or rhesus compatibility and irregular agglutinins.

Results: Seventy-two patients were included. Regarding ABO mismatch, there was no difference in terms of death (51% vs. 43%, P = 0.820), thrombosis (25% vs. 32%, P = 0.78), rupture (9% vs. 0%, P = 0.247), stenosis (3% vs. 12%, P = 0.331), aneurysmal degeneration (16% vs. 12%, P = 1), and 5 years of secondary patency rate (34% vs. 39%, P = 0.141). There was also no difference regarding Rhesus mismatch.

Conclusions: Allograft degeneration does not seem to be related to ABO mismatch. This degeneration could be related to another way of immunogenicity, particularly Human Leukocyte Antigen mismatch, and needs further exploration.

MeSH terms

  • ABO Blood-Group System / immunology*
  • Allografts
  • Aneurysm / immunology
  • Aneurysm / physiopathology
  • Arteries / immunology
  • Arteries / physiopathology
  • Arteries / transplantation*
  • Bioprosthesis*
  • Blood Vessel Prosthesis Implantation / adverse effects
  • Blood Vessel Prosthesis Implantation / instrumentation*
  • Blood Vessel Prosthesis Implantation / mortality
  • Blood Vessel Prosthesis*
  • Cryopreservation*
  • Female
  • Graft Occlusion, Vascular / immunology
  • Graft Occlusion, Vascular / physiopathology
  • Graft Rejection / immunology
  • Graft Survival
  • Histocompatibility*
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Retrospective Studies
  • Rh-Hr Blood-Group System / immunology*
  • Risk Factors
  • Thrombosis / immunology
  • Thrombosis / physiopathology
  • Time Factors
  • Treatment Outcome
  • Vascular Patency

Substances

  • ABO Blood-Group System
  • Rh-Hr Blood-Group System